ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
37 announcements
Aarti Drugs reported FY26 revenue of ₹2,568 Cr (+7% YoY) and PAT of ₹195 Cr (+16% YoY). Q4 saw strong sequential recovery with 20% revenue growth, driven by Sayakha facility scale-up.
Aarti Drugs reported FY26 revenue of ₹2,568 Cr (+7% YoY) and PAT of ₹195 Cr (+16% YoY), driven by the Sayakha facility scale-up and improved export traction despite pricing pressures.
Aarti Drugs reported FY26 revenue of ₹2,567.7 Crore, reflecting 7% year-on-year growth. Net profit reached ₹194.9 Crore, driven by strong sequential recovery and operational scale-up.
Aarti Drugs Ltd reported revenue from operations of ₹720.3 Cr (+6.4% YoY) and net profit of ₹55.3 Cr (-11.9% YoY) for Q4 FY26.
Aarti Drugs scheduled a board meeting for May 15, 2026, to approve annual audited financial results. The trading window remains closed until 48 hours after declaration.
Aarti Drugs Limited submitted a compliance certificate for the quarter ended March 31, 2026, regarding the dematerialisation of securities. The certificate, issued by MUFG Intime India, confirms that security certificates received were processed and listed on exchanges within prescribed timelines. This is a routine regulatory disclosure.
Aarti Drugs Ltd launched the 'Saksham Niveshak' campaign from April to July 2026, following MCA guidelines. The initiative encourages shareholders to update KYC details to claim unpaid dividends before they transfer to the IEPF. This improves investor relations and ensures compliance with dividend distribution regulations.